Editorial: Squeezing tubes: A case of remodeling and regulation: Coronary reserve in hypertensive heart disease

Cardiovascular Research

Volumn 40, Issue 1, 1998, Pages 4-8

  Schwartzkopff, B ^a   Strauer, B E ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; ISRADIPINE; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; CARDIOMYOPATHY; CARDIOVASCULAR AUTOREGULATION; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; DRUG INDICATION; EDITORIAL; ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; BIOLOGICAL MODEL; CORONARY ARTERY DISEASE; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; REVIEW; VASODILATATION;

CORONARY DISEASE; HUMANS; HYPERTENSION; MODELS, CARDIOVASCULAR; VASODILATION; VENTRICULAR REMODELING;

EID: 0032176337     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00174-6     Document Type: Editorial

References (30)

1. [1] Levy D, Larson MG, Vasan R, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. J Am Med Assoc 1996;275:1557-1562.
2. [2] Strauer BE. Ventricular function and coronary hemodynamics in hypertensive heart disease. Am J Cardiol 1979;44:999-1006.
3. [3] Brush JE, Cannon RO III, Schenke WH. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. New Engl J Med 1988;318:1302-1307.
4. [4] Iriarte M, Caso R, Murga N, et al. Microvascular angina pectoris in hypertensive patients with left ventricular hypertrophy and diagnostic value of exercise thallium-201 scintigraphy. Am J Cardiol 1995;75:335-339.
5. [5] Hoffman J. Maximal coronary flow and the concept of coronary vascular reserve. Circulation 1984;70:153-159.
6. [6] Duncker DJ, Zhang J, Bache RJ. Coronary pressure-flow relation in left-ventricular hypertrophy. Importance of changes in back pressure versus changes in minimum resistance. Circ Res 1993;72:579-587.
7. [7] Tomanek RJ. Response of the coronary vasculature to myocardial hypertrophy. J Am Coll Cardiol 1990;15:528-533.
8. [8] Muller JM, Davis MJ, Chilian WM. Integrated regulation of pressure and flow in the coronary microcirculation. Cardiovasc Res 1996;32:668-678.
9. [9] Chilian WM, with contributions from the NHLBI Workshop Participants. Coronary microcirculation in health and disease. Summary of an NHLBI Workshop. Circulation 1997;95:522-528.
10. [10] Bishop Sp, Powell PC, Hasebe N, et al. Coronary vascular morphology in pressure-overload left ventricular hypertrophy. J Moll Cell Cardiol 1996;28:141-154.
11. [11] Parodi O, Neglia D, Palombo C, et al. Comparative effects of enalapril and verapamil on myocardial blood flow in systemic hypertension. Circulation 1997;96:864-873.
12. [12] Antony I, Nitenberg A, Foult JM, Aptecar E. Coronary vasodilator reserve in untreated and treated hypertensive patients with and without left ventricular hypertrophy. J Am Coll Cardiol 1993;22:514-520.
13. [13] Treasure CB, Klein L, Vita GA, et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993;87:86-93.
14. [14] Rossen JD, Winniford MD. Effect of increases in heart rate and arterial pressure on coronary flow reserve in humans. J Am Coll Cardiol 1993;21:343-348.
15. [15] Czernin J, Müller P, Chan S, et al. Influence of age and haemodynamics on myocardial blood flow and flow reserve. Circulation 1993;88:62-69.
16. [16] Resar JR, Livingston JZ, Yin FCP. In-plane myocardial wall stress is not the primary determinant of coronary systolic flow impediment: A study in isolated perfused dog septum. Circ Res 1992;70:583-592.
17. [17] Camici PG, Gropler RJ, Jones T, et al. The impact of myocardial blood flow quantitation with PET on the understanding of cardiac diseases. Eur Heart 1996;J 17:25-34.
18. [18] Weber KT, Anversa P, Armstrong W, et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 1992;20:3-16.
19. [19] Schiffrin EL, Hayoz D. How to assess vascular remodelling in small and medium-sized muscular arteries in humans. J Hypertens 1997;15:571-584.
20. [20] Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991;83:1771-1779.
21. [21] Schwartzkopff B, Motz W, Frenzel H, et al. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 1993;88:993-1003.
22. [22] Jones CJH, Kuo L, Davis MJ, DeFily DV, Chilian WM. Role of nitric oxide in the coronary microvascular responses to adenosine and increased metabolic demand. Circulation 1995;91:1807-1813.
23. [23] Shiode N, Morishima N, Nakayama K, et al. Flow-mediated vasodilation of human epicardial coronary arteries, effect of inhibition of nitric oxide synthesis. J Am Coll Cardiol 1996;27:304-310.
24. [24] Schaper W, Ito WD. Molecular mechanisms of coronary collateral vessel growth. Circ Res 1996;79:911-919.
25. [25] Lüscher TF, Wenzel RR, Noll G. Local regulation of the coronary circulation in health and disease, role of nitic oxide and endothelin. Eur Heart J 1995;16:51-58.
26. [26] Cabros M, Coste P, Paccalin M, et al. Reduced basal NO-mediated dilation and decreased endothelial NO-synthase expression in coronary vessels of spontaneously hypertensive rats. J Mol Cell Cardiol 1997;29:55-65.
27. [27] Gistri R, Ebert AG, Palombo C, et al. Effect of blood pressure lowering on coronary vasodilator reserve in arterial hypertension. Cardiovasc Drugs Ther 1994;8:169-171.
28. [28] Magrini F, Reggiani P, Roberts N, et al. Converting enzyme inhibition and coronary blood flow. Circulation 1987;75:168-174.
29. [29] Motz W, Strauer BE. Improvement of coronary flow after long-term therapy with enalapril. Hypertension 1996;27:1031-1058.
30. [30] Vogt M, Motz W, Strauer BE. Antihypertensive Langzeittherapie mit Isradipin. Arzneimittel-Forsch 1994;44:1321-1328.